B. Martín-Castillo

A. Segura‐Carretero, E. Cuyás, B. Martín-Castillo, 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Characterization of non-dominant lethal mutations in the yeast plasma membrane H+-ATPase gene.

B. Martín-Castillo, F. Portillo, 1999, Biochimica et biophysica acta.

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

J. Brunet, S. Verdura, E. Cuyás, 2019, Journal of clinical medicine.

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2‐driven cancer cell growth

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Journal of cellular physiology.

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology

S. Verdura, E. Cuyás, B. Martín-Castillo, 2021, Frontiers in Oncology.

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

S. Verdura, E. Cuyás, B. Martín-Castillo, 2021, Pharmaceuticals.

Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil

J. Lozano-Sánchez, A. Segura‐Carretero, E. López-Bonet, 2013, Cell cycle.

Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205

A. Segura‐Carretero, B. Martín-Castillo, J. Bosch-Barrera, 2012, Cell cycle.

Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells

C. López-Otín, B. Martín-Castillo, J. Menéndez, 2012, Cell cycle.

Metformin: Multi-faceted protection against cancer

B. Martín-Castillo, J. Bosch-Barrera, J. Menéndez, 2011, Oncotarget.

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer

B. Martín-Castillo, J. Menéndez, J. Joven, 2011, Aging.

Stratification of cancer and diabetes based on circulating levels of formate and glucose

Alexei Vazquez, B. Martín-Castillo, J. Menéndez, 2019, Cancer & metabolism.

Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2013 .

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

J. Encinar, J. Brunet, B. Martín-Castillo, 2020, Journal of clinical medicine.

Metformin and Breast Cancer: Where Are We Now?

B. Martín-Castillo, J. Menéndez, S. Pernas, 2022, International journal of molecular sciences.

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

E. Cuyás, E. López-Bonet, B. Martín-Castillo, 2015, Oncotarget.

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

A. Segura‐Carretero, E. Cuyás, E. López-Bonet, 2013, Oncotarget.

B. Martín-Castillo, J. Menéndez, A. Urruticoechea, 2012, Oncotarget.

Expression status of the autophagy‐regulatory gene ATG6/BECN1 in ERBB2‐positive breast carcinomas: Bypassing ERBB2‐induced oncogenic senescence to regulate the efficacy of ERBB2‐targeted therapies

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2011, Genes, chromosomes & cancer.

The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells

E. Cuyás, E. López-Bonet, B. Martín-Castillo, 2013, Cell cycle.

Autophagy positively regulates the CD44+CD24-/low breast cancer stem-like phenotype

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Cell cycle.

Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity

J. Lozano-Sánchez, A. Segura‐Carretero, S. Verdura, 2020, Aging.

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors

J. Lozano-Sánchez, A. Segura‐Carretero, S. Verdura, 2018, Carcinogenesis.

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy

S. Verdura, E. Cuyás, B. Martín-Castillo, 2020, Cancers.

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

E. Cuyás, B. Martín-Castillo, J. Bosch-Barrera, 2013, Scientific Reports.

Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

A. Segura‐Carretero, E. Cuyás, B. Martín-Castillo, 2013, Cell cycle.

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

J. Brunet, E. López-Bonet, B. Martín-Castillo, 2010, Biochemical and biophysical research communications.

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes

J. Encinar, J. Brunet, S. Verdura, 2020, Aging.

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2012, Cell cycle.

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

Javier A Menendez, Joan Brunet, J. Brunet, 2011, International journal of oncology.

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells

J. Brunet, B. Martín-Castillo, J. Menéndez, 2011, Journal of cellular biochemistry.

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype

E. Cuyás, B. Martín-Castillo, J. Bosch-Barrera, 2015, Oncotarget.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.

E. Cuyás, B. Martín-Castillo, J. Menéndez, 2017, Histology and histopathology.

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

S. Verdura, E. Cuyás, B. Martín-Castillo, 2019, Oncoimmunology.

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics

E. Cuyás, E. López-Bonet, B. Martín-Castillo, 2014, Oncotarget.

Metformin is synthetically lethal with glucose withdrawal in cancer cells

B. Martín-Castillo, J. Menéndez, J. Joven, 2012, Cell cycle.

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2015, Oncotarget.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER 2 + breast cancer

E. Cuyás, B. Martín-Castillo, J. Menéndez, 2016 .

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

J. Brunet, E. López-Bonet, B. Martín-Castillo, 2008, International journal of oncology.

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

A. Segura‐Carretero, E. Cuyás, B. Martín-Castillo, 2013, Scientific Reports.

Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2

Alexei Vazquez, J. Encinar, S. Verdura, 2021, Cancers.

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Cell cycle.

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis

B. Martín-Castillo, J. Menéndez, J. Joven, 2010, Cell cycle.

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer

E. Cuyás, E. López-Bonet, B. Martín-Castillo, 2013, Scientific Reports.

Stratification of cancer and diabetes based on circulating levels of formate and glucose

A. Vazquez, B. Martín-Castillo, J. Menéndez, 2019, Cancer & metabolism.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

A. Segura‐Carretero, S. Verdura, E. Cuyás, 2018, Oncotarget.

Metformin : a pharmacological approach integrating hyperinsulinemia and breast cancer at the molecular , cellular and clinical levels *

B. Martín-Castillo, J. Menéndez, A. Vazquez-Martin, 2019 .

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2010, Oncology reports.

Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2010, Cell cycle.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

J. Brunet, E. López-Bonet, B. Martín-Castillo, 2010, International journal of oncology.

Metformin: a pharmacological approach integrating hyperinsulinemia breast cáncer at the molecular, cellular clinical levels*

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2010 .

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs

A. Segura‐Carretero, B. Martín-Castillo, J. Menéndez, 2012, Aging.

An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2014, Scientific Reports.

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Fatty acid synthase activity regulates HER 2 extracellular domain shedding into the circulation of HER 2-positive metastatic breast cancer patients

J. Brunet, B. Martín-Castillo, J. Menéndez, 2009 .

Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.

J. Brunet, B. Martín-Castillo, J. Menéndez, 2009, International journal of oncology.

Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation

B. Martín-Castillo, J. Bosch-Barrera, J. Menéndez, 2012, Cell cycle.

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

J. Brunet, S. Verdura, E. Cuyás, 2018, Front. Endocrinol..

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

J. Lozano-Sánchez, A. Segura‐Carretero, S. Verdura, 2018, Carcinogenesis.

Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2010, Cell cycle.

Metformin directly targets the H3K27me3 demethylase KDM6A/UTX

B. Viollet, S. Verdura, E. Cuyás, 2018, Aging cell.

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

S. Verdura, E. Cuyás, B. Martín-Castillo, 2022, Aging.

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2012, Scientific Reports.

BRCA1 and acetyl‐CoA carboxylase: The metabolic syndrome of breast cancer

J. Brunet, B. Martín-Castillo, J. Menéndez, 2008, Molecular carcinogenesis.

Antibody microarray‐based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Journal of surgical oncology.

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment

A. Segura‐Carretero, E. Cuyás, B. Martín-Castillo, 2014, Oncotarget.

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Breast Cancer Research and Treatment.

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer

R. Salazar, J. Brunet, E. Cuyás, 2016, Oncotarget.

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.

B. Martín-Castillo, J. Menéndez, A. Vazquez-Martin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

B. Martín-Castillo, J. Menéndez, S. Cufí, 2010, Current molecular medicine.

Abstract P1-10-01: Safety and efficacy of neoadjuvant metformin with trastuzumab and chemotherapy in women with HER2-positive early breast cancer: A randomized, open-label, multicenter, phase 2 trial

S. Verdura, E. Cuyás, E. López-Bonet, 2018 .

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Research and Treatment The anti-diabetic drug metformin suppresses Self-renewal and proliferation of trastuzumab-resistant Tumor-initiating breast cancer stem cells

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011 .

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2011, Genes, chromosomes & cancer.

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

S. Verdura, E. Cuyás, B. Martín-Castillo, 2023, Molecular oncology.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.

E. Cuyás, B. Martín-Castillo, J. Menéndez, 2017, Histology and histopathology.

Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response

B. Martín-Castillo, J. Menéndez, A. Vázquez-Martín, 2011, Cell cycle.

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2010, Oncology reports.